PI3K inhibitors are finally coming of age

B Vanhaesebroeck, MWD Perry, JR Brown… - Nature reviews Drug …, 2021 - nature.com
Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

The critical role of Akt in cardiovascular function

P Abeyrathna, Y Su - Vascular pharmacology, 2015 - Elsevier
Akt kinase, a member of AGC kinases, is important in many cellular functions including
proliferation, migration, cell growth and metabolism. There are three known Akt isoforms …

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

IW Flinn, P Hillmen, M Montillo, Z Nagy… - Blood, The Journal …, 2018 - ashpublications.org
Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ
and γ (PI3K-δ, γ) being developed for treatment of hematologic malignancies. PI3K-δ, γ …

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif… - autophagy, 2021 - Taylor & Francis
In 2008, we published the first set of guidelines for standardizing research in autophagy.
Since then, this topic has received increasing attention, and many scientists have entered …

Phosphoinositides: tiny lipids with giant impact on cell regulation

T Balla - Physiological reviews, 2013 - journals.physiology.org
Phosphoinositides (PIs) make up only a small fraction of cellular phospholipids, yet they
control almost all aspects of a cell's life and death. These lipids gained tremendous research …

Targeting pathological B cell receptor signalling in lymphoid malignancies

RM Young, LM Staudt - Nature reviews Drug discovery, 2013 - nature.com
Signalling through the B cell receptor (BCR) is central to the development and maintenance
of B cells. In light of the numerous proliferative and survival pathways activated downstream …

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

J Hoellenriegel, SA Meadows, M Sivina… - Blood, The Journal …, 2011 - ashpublications.org
Abstract In lymphocytes, the phosphoinositide 3′-kinase (PI3K) isoform p110δ (PI3Kδ)
transmits signals from surface receptors, including the B-cell receptor (BCR). CAL-101, a …

Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation …

Q Ping Dou, JA Zonder - Current cancer drug targets, 2014 - ingentaconnect.com
Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

N Mimura, M Fulciniti, G Gorgun, YT Tai… - Blood, The Journal …, 2012 - ashpublications.org
Multiple myeloma (MM) cells are characterized by high protein synthesis resulting in chronic
endoplasmic reticulum (ER) stress, which is adaptively managed by the unfolded protein …

B cell receptor signaling in chronic lymphocytic leukemia

JA Burger, N Chiorazzi - Trends in immunology, 2013 - cell.com
B cell receptor (BCR) signaling plays an important pathogenic role in chronic lymphocytic
leukemia (CLL) and B cell lymphomas, based on structural restrictions of the BCR, and BCR …